文献速递血栓与止血

Rilzabrutinib治疗经治免疫性血小板减少症:LUNA3开放标签期结果

Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial.
PubMed 文献 · Lancet Haematol · 2026-09-17

LUNA3是一项多中心随机3期试验,在103个中心24个国家入组成人及青少年持续性或慢性原发性ITP患者,双盲期后进入28周开放标签期接受rilzabrutinib 400mg每日两次口服。198例暴露于rilzabrutinib的患者中46例(23%)达稳定血小板应答,治疗相关不良事件以1-2级腹泻和恶心最常见,无死亡发生。

要点

  • 经治ITP患者中rilzabrutinib稳定血小板应答率23%(46/198)。
  • 治疗相关不良事件多为1-2级腹泻和恶心,各占9%。
  • 3级治疗相关不良事件4例(2%),严重治疗相关不良事件2例(1%)。

核心结论

  • Rilzabrutinib在开放标签期显示持续、稳定且部分改善的血小板应答,包括双盲期初始无应答者。
  • Rilzabrutinib改善身体疲劳和出血等疾病方面,支持其多免疫调节机制,安全性良好。

研究设计与样本

  • LUNA3为多中心随机3期试验,在24国103个中心入组≥18岁原发性持续性或慢性ITP且既往对IVIG或抗D免疫球蛋白或糖皮质激素有应答的成人患者。
  • 双盲期按2:1随机接受rilzabrutinib 400mg每日两次口服或安慰剂,完成24周双盲期或第12周未达预设应答标准者进入28周开放标签期接受rilzabrutinib 400mg每日两次。
  • 2021年4月16日至2024年10月15日,双盲期随机202例中180例进入开放标签期(双盲rilzabrutinib组115例,安慰剂组65例),中位年龄48岁(IQR 33-61),女性112例(62%),男性68例(38%),白人113例(63%)。

主要发现

  • 截至2024年10月15日,双盲及开放标签期暴露于rilzabrutinib的198例患者中46例(23%)达稳定血小板应答(双盲rilzabrutinib组31/133[23%],双盲安慰剂组15/65[23%])。
  • 治疗相关不良事件发生于180例中的46例(26%),最常见为1或2级腹泻(17例[9%])和恶心(17例[9%])。
  • 治疗相关3级不良事件4例(2%),分别为高血压、瘀点、间质性肺病、支气管肺曲霉病合并巨细胞病毒血症各1例。
  • 严重治疗相关不良事件2例(1%),分别为间质性肺病和支气管肺曲霉病合并巨细胞病毒血症;开放标签期无死亡。

关键数值与推荐

  • 稳定血小板应答定义:双盲及开放标签期内无两次间隔至少4周的血小板计数<50×10^9/L,且初始血小板应答后24周内无介入计数≥50×10^9/L。
  • 持久应答定义:开放标签期最后16周(共28周)内至少10次非缺失周血小板计数中至少三分之二≥50×10^9/L且未用救援治疗。
  • 完全应答定义:至少间隔5天的连续两次访视血小板计数≥100×10^9/L且无出血或未用救援ITP治疗。

临床怎么用

  • Rilzabrutinib 400mg每日两次口服可为经治ITP患者提供持续血小板应答,需关注腹泻、恶心及少见3级不良事件。
  • 开放标签期结果支持在双盲期无应答者中继续观察rilzabrutinib的潜在获益。

局限性

  • 开放标签期无对照组,结果需谨慎解读。
  • 随访中位196天,长期疗效和安全性需等待LUNA3延长随访期及LUNA4试验进一步明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rilzabrutinib showed robust efficacy and favourable safety profile in patients with persistent or chronic immune thrombocytopenia in the double-blind period of the phase 3 LUNA3 trial. We report long-term activity and safety of rilzabrutinib in the LUNA3 open-label period. METHODS: LUNA3 was a multicentre, randomised, phase 3 trial that was done at 103 centres in 24 countries in adolescents and adults. In this study, adults aged 18 years or older with primary persistent or chronic immune thrombocytopenia with a previous response to intravenous or anti-D immunoglobulins or corticosteroids were enrolled during the double-blind period and were randomised 2:1 to receive either rilzabrutinib 400 mg twice daily orally or placebo. Patients entered the 28-week open-label period either after completing the 24-week double-blind period or after week 12 if they did not meet predefined response criteria, in which they received rilzabrutinib 400 mg twice daily orally. Endpoints of this open-label study were evaluated as secondary (stable platelet response over the double-blind and open-label periods [no two platelet counts, at least 4 weeks apart, <50 × 109 platelets per L, without an intervening count of ≥50 × 109 platelets per L, within 24 weeks of initial platelet response] and safety) and exploratory (proportion of patients who received either placebo or rilzabrutinib during the double-blind period and had a durable response during the open-label period [platelet counts ≥50 × 109 platelets per L for at least two-thirds of at least ten non-missing weekly platelet counts during the last 16 of 28 weeks of the open-label period without rescue therapy]; complete response [platelet count ≥100 × 109 platelets per L on two consecutive visits at least 5 days apart without bleeding or rescue immune thrombocytopenia therapy]; Immune Thrombocytopenic Purpura Patient Assessment Questionnaire physical fatigue score; and immune thrombocytopenic purpura bleeding scale score). Activity and safety analyses were done in patients exposed to rilzabrutinib during the double-blind and open-label periods according to the intention-to-treat principle. This trial is registered with ClinicalTrials.gov (NCT04562766) and the EU Clinical Trials Register (2023-509401-71); the adult part of the trial is complete. FINDINGS: Between April 16, 2021, and Oct 15, 2024, 180 patients of the 202 patients randomly assigned during the double-blind period entered the open-label period (115 who were randomly assigned to rilzabrutinib and 65 to placebo during the double-blind period; median age 48 years [IQR 33-61], 112 [62%] females and 68 [38%] males, and 113 [63%] White). 46 (23%) of 198 patients exposed to rilzabrutinib in the double-blind and open-label periods had stable platelet responses by the data cutoff date of Oct 15, 2024 (31 [23%] of 133 in the double-blind rilzabrutinib group and 15 [23%] of 65 in the double-blind placebo group). Treatment-related adverse events occurred in 46 (26%) of 180 patients, of which the most frequent were grade 1 or 2 diarrhoea (17 [9%] patients) and nausea (17 [9%]). Treatment-related grade 3 adverse events occurred in four (2%) patients (one had hypertension, one had petechiae, one had interstitial lung disease, and one had bronchopulmonary aspergillosis and cytomegalovirus viraemia). Serious treatment-related adverse events occurred in two (1%) patients (interstitial lung disease and bronchopulmonary aspergillosis along with cytomegalovirus viremia). No deaths occurred during the open-label period. 14 (22%) of 65 patients in the double-blind placebo group had a durable platelet response). Median follow-up was 196 days (IQR 89-197). Complete response was attained by 42 (23%) of 180 patients. Physical fatigue (maximum mean change from baseline of 11·7 [SD 27·4] across all patients) and bleeding scores (mean change from baseline of -0·13 [SD 0·19]) were sustained or improved. INTERPRETATION: Rilzabrutinib showed continued, stable, and sometimes improved platelet responses, including in patients who were initially non-responsive in the double-blind trial. Additionally, rilzabrutinib improved several disease aspects, including physical fatigue and bleeding, supporting its multi-immune modulation mechanism in immune thrombocytopenia, and had a favourable safety profile. The long-term extension period of LUNA3 will further characterise the long-term efficacy and safety of rilzabrutinib in patients with difficult-to-treat immune thrombocytopenia, and the ongoing LUNA4 trial (NCT07007962) will determine the efficacy of rilzabrutinib in earlier-line treatment and its potential to achieve sustained treatment-free response. FUNDING: Sanofi. TRANSLATIONS: For the German, French, Japanese, Spanish, Arabic and Italian translations of the abstract see Supplementary Materials section.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Kuter DJ, Ghanima W, Cooper N, et al. Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial. Lancet Haematol. 2026. PMID: 42753771. doi:10.1016/S2352-3026(26)00193-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。